Regeneron’s Veopoz (pozelimab-bbfg) Receives the US FDA’s Approval as First Treatment For Children and Adults With Chaple Disease
Shots:
- The US FDA has approved Veopoz for adult & pediatric patients aged ≥1yr. with CHAPLE disease. The approval was based on the P-II/III open-label trial of pozelimab
- Patients received a single loading dose of pozelimab (30mg/kg, IV on day 1), followed by weight-based doses SC, qw. The results showed normalization of serum albumin at 12wks. & maintained serum albumin concentrations through 72wks. of treatment, the median time for serum albumin to reach 3.5g/dL was reported to be 15.5days with a reduction in total no. of albumin transfusions & hospitalization days
- Veopoz is supplied as 400mg/2mL solution in a single-dose vial. Regeneron’s myRARE patient support program incl. assistance focused on the needs of eligible patients, incl. insurance coverage, financial support & information on treatment
Ref: Regeneron | Image: Regeneron
Related News:- Regeneron Reports Two-Year (PULSAR) Trial Results of Aflibercept for Wet Age-Related Macular Degeneration
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
